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Abstract Tamoxifen (TAM), a widely used agent in the hormo- 
nal therapy of breast cancer, is also an antagonist of P-glycopro- 
tein (P-gp), a cell surface protein which confers drug resistance 
to cells. Here we report that in an estrogen receptor-deficient 
multidrug-resistant subline of MCF-7 human breast carcinoma 
cells (MCF-71MDR), but not in the parent drug-sensitive cells 
(MCF-7/WT), clinically relevant concentrations (1-5 ~M) of 
TAM inhibited the uptake and phosphorylation of ethanolamine 
and choline. These inhibitory effects resulted in decreased synthe- 
sis of the corresponding phospholipids. In view of the known 
dependence of P-gp function on phosphatidylethanolamine 
(PtdEtn), inhibition of PtdEtn synthesis may represent an addi- 
tional mechanism by which TAM inhibits P-gp-mediated rug 
efflux. 
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known whether interaction with P-gp is the only mechanism by 
which TAM inhibits P-gp-mediated drug eftlux, 
Recent evidence has indicated that the ATP-dependent func- 
tion of P-gp requires phosphatidylethanolamine (PtdEtn) [11]. 
It has also been amply documented that TAM is capable of 
decreasing both membrane fluidity in model and native mem- 
branes [12-14] and drug efftux from liposomes [15]. Based on 
these observations, it was of interest o examine the effects of 
TAM on the uptake and metabolism of phospholipid precur- 
sors leading to phospholipid synthesis. Here we report that in 
MCF-7/MDR cells, but not in MCF-7/WT cells, TAM inhib- 
ited the uptake and phosphorylation f ethanolamine (Etn) and 
choline (Cho) and, as a result, the synthesis of corresponding 
phospholipids. 
2. Materials and methods 
I. Introduction 
Increased expression of P-glycoprotein (P-gp), a membrane 
glycoprotein of 170 kDa encoded by the multidrug resistance 
(MDR)-I  gene, in culture cells has been shown to confer both 
intrinsic and acquired resistance to anti-neoplastic drugs [1-3]. 
A wide range of compounds have been shown to be transported 
out of cells by P-gp [4]. It has been suggested that increased 
transport of P-gp substrates i associated with poorer antago- 
nistic properties, while P-gp antagonists are more poorly trans- 
ported than the typical substrates [5]. This, in principle, may 
provide an opportunity to enhance the cytotoxic effects of 
drugs by using them in combination with a P-gp antagonist. 
Tamoxifen (TAM), a triphenylethylene on-steroidal anti- 
estrogen, has been extensively used for treatment of patients 
with all stages of breast cancer [6-8]. In addition to its growth 
inhibitory effects, TAM has also been shown to be an antago- 
nist of P-gp [9]. In accordance with the above prediction [5], in 
a multidrug-resistant subline of MCF-7 human breast carci- 
noma cells (MCF-7/MDR), but not in the drug-sensitive parent 
cells (MCF-7/WT), TAM was shown to enhance the cytotox- 
icity of vinblastine and doxorubicin [10]. However, it is not 
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2.1. Materials 
TAM and Dowex-50W [H +] form were purchased from Sigma; [2- 
14C]ethanolamine (50mCi/mmol) and [methyl-t4C]choline chloride (55 
mCi/mmol) were from Amersham; tissue culture reagents were bought 
from Gibco BRL. 
2.2. Cell culture 
The MCF-7 human breast cancer cell lines (drug-sensitive MCF-7/ 
WT cells and multidrug-resistant MCF-7/MDR cells) were generously 
provided by Dr. Kenneth Cowan (National Cancer Institute, NIH, 
Bethesda, MD, USA). MCF-7 cells were maintained as described ear- 
lier [16]. 
2.3. Determination of cellular uptake, phosphorylation, and 
incorporation into phospholipids of [14C]Etn and [~4C]Cho in 
MCF-7 cells' 
MCF-7/MDR and MCF-7/WT cells were similarly grown in 12-well 
tissue culture dishes to 90-100% confluency, so the surface area covered 
by these cells was practically the same in each experiment. Cells were 
incubated with TAM (1-5 /IM) for 45 min in choline-free Richer's 
Iscove's mediated Eagle medium, followed (with no washing step being 
included) by incubation of cells for 0-3 h in the presence of 50 ¢tM 
[14C]Etn (2 x 106 dpm/well) or 50 ~tM [14C]Cho (2 × 106 dpm/well). At 
the end of incubation, the incubation medium was aspirated, then cells 
were gently but rapidly (within 20 s) washed with 5 ml medium followed 
by the addition of ice-cold methanol (2 ml) to the wells. Then, cells were 
scraped into methanol, and methanol extracts were rapidly transferred 
to 2 ml of chloroform. The water-soluble metabolites of [~4C]Etn and 
[14C]Cho were fractionated on Dowex-50W [H+]-packed columns (Bio- 
Rad; Econo columns, 1 ml bed volume) as described by Cook and 
Wakelam [17] with some modifications as follows. The initial flow- 
through (4.5 ml) along with a following 3.5- to 5-ml water wash con- 
tained glycerophosphoethanolamine and glycerophosphocholine, r -
spectively. Ethanolamine phosphate (EtnP) and choline phosphate 
(ChoP) were eluted by 15 and 20 ml water, respectively. Finally, Etn 
and Cho were eluted by 12 and 20 ml of 1 M HCI, respectively. The 
metabolites of[~4C]Etn and [14C]Cho were identified and phospholipids 
were separated as indicated previously [18]. 
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3. Results 
A 
Addition of TAM (1-5/~M) to MCF-7/WT cells failed to 
significantly modify the uptake of [=4C]Etn (Fig. 1A). At each 
time point examined, MCF-7/MDR cells (Fig. 1B) contained 
about 50% less [laC]Etn compared to the drug-sensitive c lls. 
In addition, in the MDR cells TAM decreased the cellular 
content of [~4C]Etn in a dose-dependent manner (Fig. 1B). 
In MCF-7/WT cells, the major [=4C]Etn-labeled component 
was [14C]EtnP (Fig. 1C), indicating the presence of a very active 
Cho/Etn kinase. In these cells, TAM slightly, but consistently, 
enhanced the cellular level of [~4C]EtnP (Fig. 1C); the mech- 
anism and possible significance of this TAM effect is presently 
unknown. In TAM-treated MCF-7/WT cells, increased forma- 
tion of [~4C]EtnP did not lead to increased ~4C-labeling of 
PtdEtn (Fig. 1E). In MCF-7/MDR cells, TAM only slightly 
decreased the formation of [~4C]EtnP (Fig. 1D), while 2.5-5/IM 
concentrations of TAM greatly reduced the formation of 
[~4C]PtdEtn (Fig. 1F). Presently we are investigating the possi- 
bilities that the larger inhibitory effects of TAM on [~4C]PtdEtn 
formation are due to multiple inhibitory effects of TAM, or 
reflect the existence of a specific TAM-sensitive cellular pool 
of Etn which is primarily involved in PtdEtn synthesis. Here, 
we still should draw attention to the finding that despite the 
relatively large (~2.5-fold) differences in the formation of 
[14C]EtnP in the two cell lines (Fig. 1C and D), cellular PtdEtn 
pools in the drug-sensitive (Fig. 1E) and MDR (Fig. IF) lines 
were labeled by [14C]Etn roughly to the same extents. 
Incubation of MCF-7/WT cells with [IaC]Cho resulted in 
significant labeling of cellular pools of [14C]Cho (Fig. 2A), 
[14C]ChoP (Fig. 2C) and [laC]PtdCho (Fig. 2E). Again, the 
cellular ChoP pool contained about 10- to 12-fold more =4C- 
label than the cellular pools of Cho and PtdCho. These data 
indicated that in these cells, Cho is efficiently phosphorylated 
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Fig. 1. Uptake and metabolism of [~4C]Etn i  MCF-7/WT and MCF-7/MDR cells. MCF-7/WT (A, C, E) and MCF-7/MDR (B, D, F) cells, grown 
in 12-well culture dishes up to 90-100% confluency, were untreated (e), or were treated with 1/IM (A), 2.5 pM (m), or 5 pM (*) TAM for 45 rain. 
At this time point, each well received (without removing TAM) [~4C]Etn, as described in section 2, and incubations continued up to 3 h. Incorporation 
of exogenous [~4C]Etn i to the cellular pool of [JaC]Etn (A,B), [~4C]EtnP (C,D) and [~4C]PtdEtn (E,F) was determined as described in section 2. Each 
point represents he mean + S.E.M. of six independent incubations. Similar results were obtained in two other experiments, each performed in 
triplicate, using the 3 h time point. 
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by Cho kinase, and that formation of ChoP is not the rate- 
limiting step in the synthesis of PtdCho. Treatment of MCF-7/ 
WT cells for 1-3 h with TAM (1-5 pM) failed to significantly 
modify the uptake (Fig. 2A), phosphorylation (Fig. 2C), or 
incorporation of [14C]Cho into PtdCho (Fig. 2E). 
MCF-7/MDR cells exhibited dramatically lower rates of 
[laC]Cho uptake (Fig. 2B), [=4C]ChoP formation (Fig. 2D), or 
[14C]PtdCho synthesis (Fig. 2F), compared to MCF-7/WT cells. 
In addition, at each time period (1-3 h), TAM inhibited the 
accumulation of [14C]Cho (Fig. 2B), [~4C]ChoP (Fig. 2D) and 
[14C]PtdCho (Fig. 2F) to varying degrees. After incubation for 
3 h, 5/~M TAM inhibited all these processes by 50% or more. 
As it was observed in the case of PtdEtn formation, ~4C-labeling 
of PtdCho was inhibited to the greatest extent by TAM. It 
remains to be determined whether this reflects additional inhi- 
bition of PtdCho synthesis at a step beyond Cho uptake, or it 
is due to the utilization of a specific TAM-sensitive cellular pool 
of Cho for PtdCho synthesis. 
4. Discussion 
We showed that 1-5 pM concentrations of TAM, which 
appear to be physiologically relevant [19-21], significantly in- 
hibited the labeling of both PtdEtn and PtdCho by 14C-labeled 
precursors in MCF-7/MDR cells, but not in the parent drug- 
sensitive cells. Since these cells contain relatively high levels of 
EtnP and ChoP, and because these intermediates normally do 
not limit phospholipid synthesis [22,23], initially TAM may not 
significantly affect the net synthesis of PtdEtn and PtdCho. 
However, phospholipid synthesis will eventually become de- 
pendent on the supply of precursors from the medium, and this 
is when the inhibitory effects of TAM on the uptake of precur- 
sors are expected to lead to lower rates of phospholipid synthe- 
sis. 
It is presently not clear why TAM affected the metabolism 
of Etn and Cho only in the MCF-7/MDR cells. Furthermore, 
in view of the finding that different mechanisms are involved 
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Fig. 2. Uptake and metabolism of[14C]Cho in MCF-7/WT and MCF-7/MDR cells. MCF-7/WT (A, C, E) and MCF-7/MDR (B, D, F) cells, grown 
in 12-well culture dishes up to 90-100% confluency, were untreated (e), or were treated with 1/.tM (A), 2.5 ~tM (m), or 5/IM (*) TAM for 45 min. 
This was followed by the addition of [14C]Cho as described in section 2, and incubations continued up to 3 h. Incorporation ofexogenous [laC]cho 
into the cellular pool of [14C]Cho (A, B), [14C]ChoP (C, D), and [14C]PtdCho (E, F) was determined as described in section 2. Each point represents 
the mean + S.E.M. of eight independent i cubations. 
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in the uptake of Etn and Cho [24], it is not clear how TAM can 
affect both mechanisms. Nevertheless, the MDR phenotype in 
MCF-7 cells is clearly associated with significant changes in the 
metabolism of phospholipids. For example, we previously re- 
ported that TAM [25] and several known activators of phos- 
pholipase D [16] specifically stimulated the hydrolysis of 
PtdEtn in MCF-7/MDR, but not in MCF-7/WT cells. Collec- 
tively, these data suggest that the effects of TAM on phospho- 
lipid synthesis and degradation somehow reflect its binding to 
P-gp. However, until further experiments prove this possibility, 
we also have to consider the possibility that the effects of TAM 
on phospholipid metabolism do not involve P-gp. 
Finally, it is worth noting that in the same MCF-7/MDR cell 
line that was used in this work, similar concentrations of TAM 
which inhibited phospholipid labeling/synthesis (this work) 
were also shown to enhance the cytotoxic effects of vinblastine 
and doxorubicin [10]. These enhancing effects of TAM appar- 
ently reflected its binding to P-gp, resulting in the inhibition of 
efftux of vinblastine and doxorubicin [10]. Nevertheless, the 
question remains whether this is the sole mechanism by which 
TAM can decrease the functional activity of P-gp. In view of 
recent findings that PtdEtn is required for the activity of P-gp 
[11], stimulation of PtdEtn hydrolysis [16] and inhibition of 
PtdEtn synthesis (this work) may provide additional mecha- 
nisms by which TAM can inhibit P-gp-mediated fflux of cyto- 
toxic drugs. Considering the importance of this subject, further 
experiments are warranted to examine this possibility. 
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